Schonfeld Strategic Advisors LLC Sells 60,900 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Schonfeld Strategic Advisors LLC reduced its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 68.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,400 shares of the company's stock after selling 60,900 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Kiniksa Pharmaceuticals were worth $562,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its position in Kiniksa Pharmaceuticals by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $3,955,000. ExodusPoint Capital Management LP increased its holdings in shares of Kiniksa Pharmaceuticals by 965.2% during the fourth quarter. ExodusPoint Capital Management LP now owns 127,161 shares of the company's stock valued at $2,515,000 after acquiring an additional 115,223 shares in the last quarter. Globeflex Capital L P raised its position in shares of Kiniksa Pharmaceuticals by 217.1% during the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after purchasing an additional 60,656 shares during the period. Finally, Oberweis Asset Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals by 18.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 237,200 shares of the company's stock worth $4,692,000 after purchasing an additional 36,200 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $26.09 on Friday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The firm has a market capitalization of $1.90 billion, a P/E ratio of -186.34 and a beta of 0.07. The company's 50-day moving average is $22.40 and its 200 day moving average is $21.34.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. During the same quarter last year, the firm earned ($0.25) EPS. The company's quarterly revenue was up 72.5% compared to the same quarter last year. On average, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Ross Moat sold 23,234 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $28.02, for a total transaction of $651,016.68. Following the completion of the transaction, the insider now owns 9,415 shares in the company, valued at approximately $263,808.30. This represents a 71.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 242,768 shares of company stock worth $5,865,486. 54.57% of the stock is owned by company insiders.

Analyst Ratings Changes

KNSA has been the subject of a number of recent research reports. Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.